title: Long term outcome of benign childhood epilepsy with centrotemporal spikes: Dutch Study of Epilepsy in Childhood.
abstract: OBJECTIVE
  To determine long-term outcome in a cohort of children with newly diagnosed benign childhood epilepsy with centrotemporal spikes (BECTS).
  
  
  METHODS
  29 children with BECTS were included in the Dutch Study of Epilepsy in Childhood. Each child was followed for 5 years, and subsequently contacted 12-17 years after enrolment to complete a structured questionnaire. Twenty children had typical BECTS, nine had atypical BECTS (age at onset <4 years, developmental delay or learning difficulties at inclusion, other seizure types, atypical EEG abnormalities).
  
  
  RESULTS
  Mean age at onset of epilepsy was 8.0 years with slight male preponderance. Most common seizure-types before enrolment were generalized tonic-clonic seizures (GTCS) and simple partial seizures; in 86% of the children seizures occurred during sleep. After 12-17 years, 96% had a terminal remission (TR(F)) of more than 5 years and 89% of more than 10 years. Mean duration of epilepsy was 2.7 years; mean age at reaching TR(F) was 10.6 years. Many children (63%) had experienced one or more (secondary) GTCS. Antiepileptic drugs were used by 79% of the children with a mean duration of 3.0 years. None of the children seemed to have developed learning problems or an arrest of cognitive development during follow-up. No significant differences were observed in patient characteristics or outcome between children with typical BECTS and children with atypical BECTS.
  
  
  CONCLUSIONS
  All children in our cohort, both those with typical and atypical BECTS, had a very good prognosis with high remission rates after 12-17 years. None of the predictive factors for disease course and outcome observed in earlier studies (other seizure types, age at onset, multiple seizures at onset) were prognostic in our cohort.
authors.affiliation: Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. p.m.c.tijink@neuro.umcg.nl
authors.forename: Petra M C
authors.initials: PM
authors.lastname: Callenbach
authors.forename: Paul A D
authors.initials: PA
authors.lastname: Bouma
authors.forename: Ada T
authors.initials: AT
authors.lastname: Geerts
authors.forename: Willem Frans M
authors.initials: WF
authors.lastname: Arts
authors.forename: Hans
authors.initials: H
authors.lastname: Stroink
authors.forename: Els A J
authors.initials: EA
authors.lastname: Peeters
authors.forename: Cees A
authors.initials: CA
authors.lastname: van Donselaar
authors.forename: A C Boudewijn
authors.initials: AC
authors.lastname: Peters
authors.forename: Oebele F
authors.initials: OF
authors.lastname: Brouwer
mesh_terms: D017668:Age of Onset; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002658:Developmental Disabilities / Q000209:etiology*; D019305:Epilepsy, Rolandic / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009426:Netherlands; D011237:Predictive Value of Tests; D011379:Prognosis; D012074:Remission Induction; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants